[Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].

Article Details

Citation

Copy to clipboard

Komoto S, Miura S

[Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].

Nihon Rinsho. 2006 Aug;64(8):1487-90.

PubMed ID

16898618 [ View in PubMed

]

Abstract

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal (GI) disorder, but its pathophysiology remains unknown. 5-hydroxytryptamine (5-HT, serotonin) is an important neurotransmitter involved in the brain-gut connection. Alosetron, a 5-HT3 receptor antagonist, has been demonstrated in randomized, placebo-controlled trials (RCT) to be effective in diarrhea-predominant IBS(IBS-D). Constipation is the most common adverse event. Alosetron improved abdominal pain and discomfort and stool consistency in both female and male patients, but it did not improve other symptoms (sense of urgency, stool frequency and bloating) in male patients. Although less is known about the gender differences in therapeutic benefit, a new 5-HT3 antagonist, cilansetron, has demonstrated effectiveness in male and female IBS-D patients and is currently under clinical trials.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Cilansetron	5-hydroxytryptamine receptor 3A	Protein	Humans	Unknown	Not Available	Details